Want to see XOMA full AI Analyst Report?
XOMA Stock Chart & Stats
$39.71
$0.08(0.31%)
At close: 4:00 PM EST
$39.71
$0.08(0.31%)
Day’s Range― - ―
52-Week Range$22.29 - $45.22
Previous CloseN/A
Volume8.24K
Average Volume (3M)53.64K
Market Cap
$710.16M
Enterprise Value$596.22
Total Cash (Recent Filing)$94.96M
Total Debt (Recent Filing)$124.73M
Price to Earnings (P/E)24.3
Beta1.42
Next Earnings
Jul 30, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding17,678,741
10 Day Avg. Volume49,949
30 Day Avg. Volume53,642
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)4.60
Price to Sales (P/S)9.17
P/FCF Ratio166.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.00Price Target Upside-1.79% Downside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.79
Revenue Forecast (FY)$60.73M
Bulls Say, Bears Say
Bulls Say
Recurring Royalty Income ModelXOMA’s core business is owning royalty and contractual payment rights, creating recurring, product-linked cash flows that require low capital intensity. This model provides durable income exposure to commercial drug sales and milestone triggers without the manufacturing R&D overhead of drug developers, supporting long-term cash generation if partner products perform.
Return To Profitability And Cash GenerationThe company’s 2025 return to net profitability and the shift to positive, strengthening free cash flow in the trailing twelve months indicate improved earnings conversion and operational discipline. Sustained FCF supports debt servicing, preferred redemptions and strategic transactions, increasing financial flexibility over the medium term if cash generation remains stable.
Acquisition By Ligand (strategic Consolidation)The announced acquisition by Ligand is a structural change that can broaden scale and diversify royalty exposure across 120+ assets and seven marketed products. Integration into a larger aggregator can enhance portfolio diversification, administrative scale, and liquidity for shareholders, reducing single-asset concentration risk over the medium term.
Bears Say
Elevated LeverageLeverage above equity constrains financial flexibility and raises refinancing and interest-rate risk. With debt heavier than equity, weaker-than-expected royalty receipts or litigation outcomes could strain covenants or cash available for preferred redemptions and obligations, amplifying downside during revenue or cash-flow softness.
Earnings And Revenue VolatilityHistorical swings—from heavy losses to a strong 2025—highlight volatility driven by timing of milestones, non-operating items, and partner product performance. Such variability complicates forward cash-flow visibility and planning, increasing the risk that obligations or strategic plans may be disrupted if partner execution or market access weakens.
Weak Cash Conversion HistoryAlthough FCF turned positive recently, operating cash flow remains small relative to net income and past multi-year negative cash flows indicate earnings quality and timing risk. Persistent weak cash conversion would limit deleveraging ability and could force asset sales or restructuring under stress, undermining long-term stability.
XOMA Royalty Corporation News
XOMA FAQ
What was XOMA Royalty Corporation’s price range in the past 12 months?
XOMA Royalty Corporation lowest stock price was $22.29 and its highest was $45.22 in the past 12 months.
What is XOMA Royalty Corporation’s market cap?
XOMA Royalty Corporation’s market cap is $710.16M.
When is XOMA Royalty Corporation’s upcoming earnings report date?
XOMA Royalty Corporation’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were XOMA Royalty Corporation’s earnings last quarter?
XOMA Royalty Corporation released its earnings results on Apr 30, 2026. The company reported $0.168 earnings per share for the quarter, beating the consensus estimate of $0.128 by $0.04.
Is XOMA Royalty Corporation overvalued?
According to Wall Street analysts XOMA Royalty Corporation’s price is currently Overvalued.
Does XOMA Royalty Corporation pay dividends?
XOMA Royalty Corporation does not currently pay dividends.
What is XOMA Royalty Corporation’s EPS estimate?
XOMA Royalty Corporation’s EPS estimate is 0.18.
How many shares outstanding does XOMA Royalty Corporation have?
XOMA Royalty Corporation has 17,678,741 shares outstanding.
What happened to XOMA Royalty Corporation’s price movement after its last earnings report?
XOMA Royalty Corporation reported an EPS of $0.168 in its last earnings report, beating expectations of $0.128. Following the earnings report the stock price went down -0.122%.
Which hedge fund is a major shareholder of XOMA Royalty Corporation?
Currently, no hedge funds are holding shares in XOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XOMA Royalty Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$39.00 (-1.79% Downside)
$39.00 (-1.79% Downside)
Hedge Fund Trend
Increased
By 377.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.78%
Trailing 12-Months
Company Description
XOMA Royalty Corporation
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
XOMA Stock 12 Month Forecast
Average Price Target
$39.00
▼(-1.79% Downside)
Technical Analysis
Ocugen
―
Corvus Pharmaceuticals
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
3.99% Insiders
14.99% Mutual Funds
0.06% Other Institutional Investors
77.52% Public Companies and
Individual Investors